Maria Cabanillas, M.D. on thyroid cancer
Maria E. Cabanillas, M.D.
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
About Dr. Cabanillas
Maria E. Cabanillas, M.D. is an Oncologic Endocrinologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. She is a tenured Professor and the Faculty Director of Clinical Research in the department of Endocrine Neoplasia at MD Anderson.
As a clinician and clinical researcher, she treats both early and advanced thyroid cancers, including medullary, differentiated, and anaplastic thyroid cancers. Her research focus is in advanced and aggressive thyroid cancer, with an emphasis that includes molecular targeted therapies and immunotherapy. Dr. Cabanillas led the effort to create FAST, Facilitating Anaplastic thyroid cancer Specialized Treatment at MD Anderson. This multidisciplinary group sees the highest volume of anaplastic thyroid cancer patients in the nation. They have focused their efforts on streamlining the process to see these complex patients, tailor treatment plans based on the molecular abnormalities in the tumor, and designing clinical trials for this patient population.
Dr. Cabanillas serves as the principal investigator on several clinical trials for the treatment of advanced thyroid cancer and serves on the 2020 anaplastic thyroid cancer guidelines committee for the American Thyroid Association. She has been a member of the International Thyroid Oncology Group (ITOG) since 2012 and completed her term on the Board of Directors in 2020.
Present Title & Affiliation
Primary Appointment
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Research Interests
My research interests include systemic therapy for aggressive thyroid cancers (including anaplastic, poorly differentiated, papillary, follicular and medullary thyroid cancers) with targeted and immunotherapy.
Education & Training
Degree-Granting Education
| 1998 | The University of Puerto Rico Medical School, San Juan, PRI, MD, Medicine |
Postgraduate Training
| 2007-2009 | Fellowship, Division of Diabetes, Endocrinology and Metabolism, Baylor College of Medicine, Houston, TX |
| 1998-2001 | Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX |
Board Certifications
| 2009 | Diabetes, Endocrinology and Metabolism |
| 2001 | Internal Medicine |
Experience & Service
Academic Appointments
Assistant Professor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2003 - 2007
Instructor, Department of General Internal Medicine, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2001 - 2003
Administrative Appointments/Responsibilities
Faculty Director of Clinical Research, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2011 - 2023
Other Appointments/Responsibilities
Member, American Thyroid Association Clinical Affairs Committee, Falls Church, VA, 2013 - 2014
Institutional Committee Activities
Member, Institutional Review Board 2, 2017 - 2022
Vice-Chair, Institutional Review Board 1, 2013 - 2019
Member, Clinical Research Committee II, 2003 - 2007
Honors & Awards
| 2022 | The Jack and Beverly Randall Prize for Excellence in Cancer Treatment, The University of Texas MD Anderson Cancer Center |
| 2021 | Physicians Referral Service and Patient Experience Top 10% Provider, The University of Texas MD Anderson Cancer Center |
| 2020 | Division of Internal Medicine Excellence Award in Patient Care, The University of Texas MD Anderson Cancer Center |
| 2016 | Division of Internal Medicine Excellence Award in Quality, The University of Texas MD Anderson Cancer Center |
| 2011 | James S. and Suzanne Cyrus Scholar Award Finalist, Division of Internal Medicine Research Retreat |
| 2010 | James S. and Suzanne Cyrus Scholar Award Finalist, Division of Internal Medicine Research Retreat |
| 2009 | ASCO Cancer Foundation Merit Award, American Society of Clinical Oncology (ASCO) |
| 2005 | Division of Internal Medicine Research Retreat Award, The University of Texas MD Anderson Cancer Center |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK. 2021 American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. Thyroid 31(3):337-386, 2021. PMID: 33728999.
- Cabanillas ME, Dadu R, Iyer P, Wanland KB, Busaidy NL, Ying A, Gule-Monroe M, Wang JR, Zafereo M, Hofmann MC. Acquired Secondary RAS Mutation in BRAFV600E Mutated Thyroid Cancer Patients Treated with BRAF Inhibitors. Thyroid 30(9):1288-1296, 2020. e-Pub 2020. PMID: 32216548.
- Jozaghi Y, Zafereo ME, Perrier ND, Wang JR, Grubbs E, Gross ND, Fisher S, Sturgis EM, Goepfert RP, Lai SY, Best C, Busaidy NL, Cabanillas ME, Dadu R, Gagel RF, Habra MA, Hu MI, Jimenez C, Sherman SI, Thosani S, Varghese J, Waguespack SG, Weitzman S, Ying AK, Graham PH. Endocrine surgery in the Coronavirus disease 2019 pandemic: Surgical Triage Guidelines. Head Neck 42(6):1325-1328, 2020. e-Pub 2020. PMID: 32437031.
- Debnam JM, Guha-Thakurta N, Sun J, Wei W, Zafereo ME, Cabanillas ME, Buisson NM, Schellingerhout D. Distinguishing Recurrent Thyroid Cancer from Residual Nonmalignant Thyroid Tissue Using Multiphasic Multi-detector Computed Tomography. AJNR Am J Neuroradiol 41(5):844-851, 2020. e-Pub 2020. PMID: 32327435.
- Boyce-Fappiano D, Gjyshi O, Pezzi TA, Allen PK, Solimman M, Taku N, Bernstein MB, Cabanillas ME, Amini B, Tatsui CE, Rhines LD, Wang XA, Briere TM, Yeboa DN, Bishop AJ, Li J, Ghia AJ. Spine Stereotactic Radiosurgery for Metastatic Thyroid Cancer: A Single Institution Experience. J Neurosurg Spine:1-9. e-Pub 2020. PMID: 32059183.
- Maxwell JE, Gule-Monroe MK, Subbiah V, Hu M, Perrier ND, Cabanillas ME, Lee JE, Graham PH, Cote GJ, Busaidy NL, Grubbs EG. Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. Surgery 167(1):80-86, 2020. e-Pub 2019. PMID: 31648931.
- Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, Massarelli E, Nguyen Q, Sharma P, Allison JP, Diab A, Verma V, Raju U, Shaaban SG, Dadu R, Cabanillas ME, Wang K, Anderson C, Gomez DR, Hahn S, Komaki R, Hong DS. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunol Res 7(12):1903-1909, 2019. e-Pub 2019. PMID: 31658994.
- Tetzlaff MT, Tang S, Duke T, Grabell DA, Cabanillas ME, Zuo Z, Yao JC, Nagarajan P, Aung PP, Torres-Cabala CA, Duvic M, Prieto VG, Huen A, Curry JL. Lichenoid dermatitis from immune checkpoint inhibitor therapy: An immune-related adverse event with mycosis-fungoides–like morphologic and molecular. J Cutan Pathol 46(11):872-877, 2019. e-Pub 2019. PMID: 31254410.
- Wang JR, Zafereo ME, Dadu R, Ferrarotto R, Busaidy NL, Lu C, Ahmed S, Gule-Monroe MK, Williams MD, Sturgis EM, Goepfert RP, Gross ND, Lai SY, Gunn GB, Phan J, Rosenthal DI, Fuller CD, Morrison WH, Iyer P, Cabanillas ME. Complete surgical resection following neoadjuvant dabrafenib plus trametinib in BRAFV600E-mutated anaplastic thyroid carcinoma. Thyroid 29(8):1036-1043, 2019. e-Pub 2019. PMID: 31319771.
- Kutahyalioglu M, Nguyen HT, Kwatampora L, Clarke C, Silva A, Ibrahim E, Waguespack SG, Cabanillas ME, Jimenez C, Hu MI, Sherman SI, Kopetz S, Broaddus R, Dadu R, Wanland K, Williams M, Zafereo M, Perrier N, Busaidy NL. Genetic profiling as a clinical tool in advanced parathyroid carcinoma. J Cancer Res Clin Oncol 145(8):1977-1986, 2019. e-Pub 2019. PMID: 31309300.
- Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM. Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling. Head Neck 41(6):1928-1934, 2019. e-Pub 2019. PMID: 30758123.
- Ye W, Hannigan B, Zalles S, Mehrotra M, Barkoh BA, Williams MD, Cabanillas ME, Edeiken-Monroe B, Hu P, Duose D, Wistuba II, Medeiros LJ, Stewart J, Luthra R, Roy-Chowdhuri S. Centrifuged Supernatants from Fine Needle Aspiration Provide a Liquid Biopsy Option for Clinical Next-Generation Sequencing of Thyroid Nodules. Cancer Cytopathol 127(3):146-160, 2019. e-Pub 2019. PMID: 30620446.
- Kazzaz FI, Cabanillas ME, Bashoura L, Shannon VR, Faiz SA. Bilateral spontaneous pneumothoraces in anaplastic thyroid cancer. Respir Med Case Rep 26:197-199, 2019. e-Pub 2019. PMID: 30705818.
- Sagiv O, Kandl TJ, Thakar SD, Thuro BA, Busaidy NL, Cabanillas M, Jimenez C, Dadu R, Graham PH, Debnam JM, Esmaeli B. Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients. Ophthalmic Plast Reconstr Surg 35(1):50-52, 2019. e-Pub 2018. PMID: 29927883.
- Angell TE, Wirth LJ, Cabanillas ME, Shindo ML, Cibas ES, Babiarz JE, Hao Y, Kim SY, Walsh PS, Huang J, Kloos RT, Kennedy GC, Waguespack SG. Analytical and Clinical Validation of Expressed Variants and Fusions from the Whole Transcriptome of Thyroid FNA Samples. Front Endocrinol (Lausanne) 10:612, 2019. e-Pub 2019. PMID: 31572297.
- Iyer PC, Cote GJ, Hai T, Gule-Monroe M, Bui-Griffith J, Williams MD, Hess K, Hofmann MC, Dadu R, Zafereo M, Busaidy NL, Ferrarotto R, Subbiah V, Gross N, Gunn BJ, Garden AS, Skinner HD, Cabanillas ME. Circulating BRAF V600E cell free DNA (cfDNA) as a biomarker in the management of Anaplastic Thyroid Carcinoma. JCO Precision Oncology 2:1-11. e-Pub 2018.
- Puli O, Danysh BP, Sinha DK, Hoang NM, Rowell R, Danysh H, Cabanillas ME, Cote GJ, Hofmann M. The transcription factor ETV5 mediates BRAFV600E-induced proliferation and TWIST1 expression in papillary thyroid cancer cells. Neoplasia, 2018.
- Jaber T, Waguespack SG, Cabanillas ME, Elbanan M, Vu T, Dadu R, Sherman SI, Amit M, Santos EB, Zafereo M, Busaidy NL. Targeted Therapy in Advanced Thyroid Cancer to Resensitize Tumors to Radioactive Iodine. J Clin Endocrinol Metab, 2018.
- Boonsripitayanon M, Tam S, Amit M, Busaidy NL, Cabanillas ME, Dadu R, Sherman S, Waguespack SG, Williams MD, Goepfert R, Gross ND, Sturgis EM, Perrier N, Zafereo ME. Survival in Differentiated Thyroid Cancer: Comparing the AJCC Cancer Staging 7th and 8th editions. Thyroid, 2018. PMID: 30141373.
- Iyer PC, Cabanillas M, Waguespack SG, Hu MI, Thosani SN, Lavis VR, Busaidy N, Subudhi SK, Diab A, Dadu R. Immune-Related Thyroiditis with Immune Checkpoint Inhibitors. Thyroid, 2018. PMID: 30132401.
- Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, Wirth LJ, Stock S, Smith S, Lauriault V, Corsi-Travali S, Henry D, Burkard M, Hamor R, Bouhana K, Winski S, Wallace RD, Hartley D, Rhodes S, Reddy M, Brandhuber BJ, Andrews S, Rothenberg SM, Drilon A. Selective RET Kinase Inhibition for Patients with RET-Altered Cancers. Ann Oncol 29(8):1869-1876, 2018. e-Pub 2018. PMID: 29912274.
- Tam S, Amit M, Boonsripitayanon M, Busaidy NL, Cabanillas ME, Waguespack SG, Gross ND, Grubbs EG, Williams MD, Lai SY, Sturgis EM, Zafereo ME. Effect of Tumor Size and Minimal Extrathyroidal Extension in Patients with Differentiated Thyroid Cancer. Thyroid 28(8):982-990, 2018. e-Pub 2018. PMID: 29936892.
- Cabanillas ME, Ferrarotto R, Garden AS, Ahmed S, Busaidy NL, Dadu R, Williams MD, Skinner H, Gunn GB, Grosu H, Iyer P, Hofmann MC, Zafereo M. Neoadjuvant BRAF- and immune- directed therapy for anaplastic thyroid carcinoma. Thyroid 28(7):945-951, 2018. e-Pub 2018. PMID: 29742974.
- Chen H, Luthra R, Routbort MJ, Patel KP, Cabanillas ME, Broaddus RR, Williams MD. Molecular Profile of Advanced Thyroid Carcinomas by Next-Generation Sequencing: Characterizing tumors beyond diagnosis for targeted therapy. Mol Cancer Ther 17(7):1575-1584, 2018. e-Pub 2018. PMID: 29695638.
- Iyer PC, Dadu R, Gule-Monroe M, Busaidy NL, Ferrarotto R, Habra MA, Zafereo M, Williams MD, Gunn GB, Grosu H, Skinner HD, Sturgis EM, Gross N, Cabanillas ME. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer, 2018.
- Amit M, Boonsripitayanon M, Goepfert RP, Tam S, Busaidy NL, Cabanillas ME, Dadu R, Varghese J, Waguespack SG, Gross ND, Graham P, Williams MD, Sturgis EM, Zafereo ME. Extrathyroidal Extension: Does Strap Muscle Invasion Alone Influence Recurrence and Survival in Patients with Differentiated Thyroid Cancer?. Ann Surg Oncol. e-Pub 2018. PMID: 30022274.
- Chavez AAL, Iyer P, Cazacu IM,, Cabanillas ME, Rashid A, Bhutani MS. Anaplastic Thyroid Carcinoma with Gastric Metastasis. Curr Health Sci J 44(3):294-298, 2018. PMID: 30647951.
- Smith AL, Williams MD, Stewart J, Wang WL, Krishnamurthy S, Cabanillas ME*, Roy-Chowdhuri S* (dual senior author). Utility of the BRAF p.V600E immunoperoxidase stain in FNA direct smears and cell block preparations from patients with thyroid carcinoma. Cancer Cytopathol 126(6):406-413, 2018. e-Pub 2018. PMID: 29579361.
- Hanna GJ, Busaidy NL, Chau NG, Wirth LJ, Barletta JA, Calles A, Haddad RI, Kraft S, Cabanillas ME, Rabinowits G, O'Neill A, Limaye SA, Alexander EK, Moore FD, Misiwkeiwicz K, Thomas T, Nehs M, Marqusee E, Lee SL, Jänne PA, Lorch JH. Genomic correlates of response to everolimus in aggressive radioiodine-refractory thyroid cancer: a phase II study. Clin Cancer Res 24(7):1546-1553, 2018. e-Pub 2018. PMID: 29301825.
- Sakamuri D, Glitza IC, Betancourt Cuellar SL, Subbiah V, Fu S, Tsimberidou AM, Wheler JJ, Hong DS, Naing A, Falchook GS, Fanale MA, Cabanillas ME, Janku F. Phase 1 dose-escalation study of anti CTLA-4 antibody ipilimumab and lenalidomide in patients with advanced cancers. Mol Cancer Ther 17(3):671-676, 2018. e-Pub 2017. PMID: 29237802.
- Ahmed S, Ghazarian MP, Cabanillas ME, Zafereo ME, Williams MD, Vu T, Schomer DF, Debnam JM. Imaging of Anaplastic Thyroid Carcinoma. AJNR Am J Neuroradiol 39(3):547-551, 2018. e-Pub 2017. PMID: 29242360.
- Amit M, Tam S, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Grubbs EG, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Association of Lymph Node Density With Survival of Patients With Papillary Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 144(2):108-114, 2018. PMID: 29192312.
- Iyer PC, Dadu R, Ferrarotto R, Busaidy NL, Habra MA, Zafereo M, Gross N, Hess KR, Gule-Monroe M, Williams MD, Cabanillas ME. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid 28(1):79-87, 2018. e-Pub 2017. PMID: 29161986.
- Pena I, Clayman GL, Grubbs EG, Bergeron JM, Waguespack SG, Cabanillas ME, Dadu R, Hu MI, Fellman BM, Li Y, Gross ND, Lai SY, Sturgis EM, Zafereo ME. Management of the Lateral Neck Compartment in Patients with Sporadic Medullary Thyroid Cancer. Head Neck 40(1):79-85, 2018. e-Pub 2017. PMID: 29044788.
- Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, Wen PY, Zielinski C, Cabanillas ME, Urbanowitz G, Mookerjee B, Wang D, Rangwala F, Keam B. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. J Clin Oncol 36(1):JCO2017736785, 2018. e-Pub 2017. PMID: 29072975.
- Tam S, Amit M, Boonsripitayanon M, Cabanillas ME, Busaidy NL, Gunn GB, Lai SY, Gross ND, Sturgis EM, Zafereo ME. Adjuvant External Beam Radiotherapy in Locally Advanced Differentiated Thyroid Cancer. JAMA Otolaryngol Head Neck Surg 143(12):1244-1251, 2017. e-Pub 2017. PMID: 29098272.
- Cabanillas ME, de Souza JA, Geyer S, Wirth LJ, Menefee ME, Liu SV, Shah K, Wright J, Shah MH. Cabozantinib As Salvage Therapy for Patients With Tyrosine Kinase Inhibitor-Refractory Differentiated Thyroid Cancer: Results of a Multicenter Phase II International Thyroid Oncology Group Trial. J Clin Oncol 35(29):JCO2017730226, 2017. e-Pub 2017. PMID: 28817373.
- Cote GJ, Evers C, Hu MI, Grubbs EG, Williams MD, Hai T, Duose DY, Houston MR, Bui JH, Mehrotra M, Waguespack SG, Busaidy NL, Cabanillas ME, Habra MA, Luthra R, Sherman SI. Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 102(9):3591-3599, 2017. PMID: 28911154.
- Voss RK, Feng L, Lee JE, Perrier ND, Graham PH, Hyde SM, Nieves-Munoz F, Cabanillas ME, Waguespack SG, Cote GJ, Gagel RF, Grubbs EG. Medullary Thyroid Carcinoma in MEN2A: ATA Moderate or High-Risk RET Mutations Do Not Predict Disease Aggressiveness. J Clin Endocrinol Metab 102(8):2807-2813, 2017. e-Pub 2017. PMID: 28609830.
- Cabanillas ME, Williams MD, Gunn GB, Weitzman SP, Burke L, Busaidy NL, Ying AK, Yiin YH, William WN, Lu C, Lai SY. Facilitating anaplastic thyroid cancer specialized treatment: A model for improving access to multidisciplinary care for patients with anaplastic thyroid cancer. Head Neck 39(7):1291-1295, 2017. e-Pub 2017. PMID: 28452157.
- Cabanillas M, Terris DJ, Sabra M. Information for Clinicians: Approach to the patient with progressive radioactive iodine refractory thyroid cancer- When to use systemic therapy. Thyroid. e-Pub 2017. PMID: 28635520.
- Rao SN, Zafereo M, Dadu R, Busaidy NL, Hess K, Cote GJ, Williams MD, William WN, Sandulache V, Gross N, Gunn GB, Lu C, Ferrarotto R, Lai SY, Cabanillas ME. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid 27(5):672-681, 2017. e-Pub 2017. PMID: 28068873.
- Pezzi TA, Mohamed ASR, Sheu T, Blanchard P, Sandulache VC, Lai SY, Cabanillas ME, Williams MD, Pezzi CM, Lu C, Garden AS, Morrison WH, Rosenthal DI, Fuller CD, Gunn GB. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: Outcomes from the National Cancer Data Base. Cancer 123(9):1653-1661, 2017. e-Pub 2016. PMID: 28026871.
- Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clin Cancer Res 23(6):1388-1396, 2017. e-Pub 2016. PMID: 27649551.
- Sandulache VC, Williams MD, Lai SY, Lu C, William WN, Busaidy NL, Cote GJ, Singh RR, Luthra R, Cabanillas ME. Real-time genomic characterization utilizing circulating cell-free DNA in patients with anaplastic thyroid carcinoma. Thyroid 27(1):81-87, 2017. e-Pub 2016. PMID: 27785980.
- Xu JY, Murphy WA, Milton DR, Jimenez C, Rao SN, Habra MA, Waguespack SG, Dadu R, Gagel RF, Ying AK, Cabanillas ME, Weitzman SP, Busaidy NL, Sellin RV, Grubbs E, Sherman SI, Hu MI. Bone Metastases and Skeletal-Related Events in Medullary Thyroid Carcinoma. J Clin Endocrinol Metab 101(12):jc20162815, 2016. e-Pub 2016. PMID: 27662441.
- Grubbs EG, Williams MD, Scheet P, Vattathil S, Perrier ND, Lee JE, Gagel RF, Hai T, Feng L, Cabanillas ME, Cote GJ. The role of CDKN2C copy number in sporadic medullary thyroid carcinoma. Thyroid 26(11):1553-1562, 2016. e-Pub 2016. PMID: 27610696.
- Xu JY, Handy B, Michaelis CL, Waguespack SG, Hu MI, Busaidy N, Jimenez C, Cabanillas ME, Fritsche HA, Cote GJ, Sherman SI. Detection and Prognostic Significance of Circulating Tumor Cells in Patients with Metastatic Thyroid Cancer. J Clin Endocrinol Metab 101(11):jc20162567, 2016. e-Pub 2016. PMID: 27575943.
- Brose MS, Cabanillas ME, Cohen EE, Wirth LJ, Riehl T, Yue H, Sherman SI, Sherman EJ. Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial. Lancet Oncol 17(9):1272-82, 2016. e-Pub 2016. PMID: 27460442.
- Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, Wang XA, Allen PK, Rhines LD, Tatsui C, Li J, Brown PD, Ghia AJ. Spine Stereotactic Radiosurgery for Patients with Metastatic Thyroid Cancer: Secondary Analysis of Phase I/II Trials. Thyroid 26(9):1269-75, 2016. e-Pub 2016. PMID: 27334245.
- Pezzi TA, Sandulache VC, Pezzi CM, Turkeltaub AE, Feng L, Cabanillas ME, Williams MD, Lai SY. Treatment and survival of patients with insular thyroid carcinoma: 508 cases from the National Cancer Data Base. Head Neck 38(6):906-12, 2016. e-Pub 2016. PMID: 26843481.
- Danysh BP, Rieger EY, Sinha DK, Evers CV, Cote GJ, Cabanillas ME, Hofmann MC. Long-Term Vemurafenib Treatment Drives Inhibitor Resistance Through a Spontaneous KRAS G12D Mutation in a BRAF V600E Papillary Thyroid Carcinoma Model. Oncotarget 7(21):30907-23, 2016. e-Pub 2016. PMID: 27127178.
- Ozsari L, Kutahyalioglu M, Elsayes KM, Vicens RA, Sircar K, Jazaerly T, Waguespack SG, Busaidy NL, Cabanillas ME, Dadu R, Hu MI, Vassilopoulou-Sellin R, Jimenez C, Lee JE, Habra MA. Preexisting adrenal masses in patients with adrenocortical carcinoma: clinical and radiological factors contributing to delayed diagnosis. Endocrine 51(2):351-9, 2016. e-Pub 2015. PMID: 26206754.
- Schlumberger M, Jarzab B, Cabanillas ME, Robinson B, Pacini F, Ball DW, McCaffrey J, Newbold K, Allison R, Martins RG, Licitra LF, Shah MH, Bodenner D, Elisei R, Burmeister L, Funahashi Y, Ren M, O'Brien JP, Sherman SI. A Phase 2 Trial of the Multi-targeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer (MTC). Clin Cancer Res 22(1):44-53, 2016. e-Pub 2015. PMID: 26311725.
- Dadu R, Hu MI, Cleeland C, Busaidy NL, Habra M, Waguespack SG, Sherman SI, Ying A, Fox P, Cabanillas ME. Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancer-Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid 25(10):1085-90, 2015. e-Pub 2015. PMID: 26200040.
- Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 121(16):2749-56, 2015. e-Pub 2015. PMID: 25913680.
- Dadu R, Shah K, Busaidy NL, Waguespack SG, Habra MA, Ying AK, Hu MI, Bassett R, Jimenez C, Sherman SI, Cabanillas ME. Efficacy and Tolerability of Vemurafenib in Patients with BRAFV600E -Positive Papillary Thyroid Cancer: M.D. Anderson Cancer Center off label experience. J Clin Endocrinol Metab 100(1):E77-81, 2015. PMID: 25353071.
- Falchook GS, Millward M, Hong D, Naing A, Piha-Paul S, Waguespack SG, Cabanillas ME, Sherman SI, Ma B, Curtis M, Goodman V, Kurzrock R. BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer. Thyroid 25(1):71-7, 2015. PMID: 25285888.
- Cabanillas ME, Hu MI, Jimenez C. Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions. J Clin Endocrinol Metab 99(12):4390-6, 2014. PMID: 25238206.
- Cabanillas ME, Brose MS, Holland J, Ferguson KC, Sherman SI. A phase I study of cabozantinib (XL184) in patients with differentiated thyroid cancer. Thyroid 24(10):1508-14, 2014. e-Pub 2014. PMID: 25102375.
- Dadu R, Devine C, Hernandez M, Waguespack SG, Busaidy NL, Hu MI, Jimenez C, Habra MA, Sellin RV, Ying AK, Cote GJ, Sherman SI, Cabanillas ME. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 99(6):2086-94, 2014. e-Pub 2014. PMID: 24628550.
- Blevins DP, Dadu R, Hu M, Baik C, Balachandran D, Ross W, Gunn B, Cabanillas ME. Aero-digestive Fistula Formation as a Rare Side Effect of Antiangiogenic Tyrosine Kinase Inhibitor Therapy for Thyroid Cancer. Thyroid 24(5):918-22, 2014. e-Pub 2014. PMID: 24635127.
- Dadu R, Waguespack SG, Sherman SI, Hu MI, Busaidy NL, Jimenez C, Habra MA, Ying AK, Bassett RL, Cabanillas ME. Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. Oncologist 19(5):477-82, 2014. e-Pub 2014. PMID: 24733667.
- Holsinger FC, Ramaswamy U, Cabanillas ME, Lang J, Lin HY, Busaidy NL, Grubbs E, Rahim S, Sturgis EM, Lee JE, Weber RS, Clayman GL, Rohren EM. Measuring the Extent of Total Thyroidectomy for Differentiated Thyroid Carcinoma Using Radioactive Iodine Imaging: Relationship With Serum Thyroglobulin and Clinical Outcomes. JAMA Otolaryngol Head Neck Surg 140(5):410-5, 2014. e-Pub 2014. PMID: 24700275.
- Thomas L, Lai SY, Dong W, Feng L, Dadu R, Regone RM, Cabanillas ME. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 19(3):251-8, 2014. e-Pub 2014. PMID: 24563075.
- Kim KB, Cabanillas ME, Lazar AJ, Williams MD, Sanders DL, Ilagan JL, Nolop K, Lee RJ, Sherman SI. Clinical responses to Vemurafenib in Patients with Metastatic Papillary Thyroid Cancer Harboring V600E BRAF mutation. Thyroid 23(10):1277-83, 2013. e-Pub 2013. PMID: 23489023.
- Carhill AA, Cabanillas ME, Jimenez C, Waguespack SG, Habra MA, Hu M, Ying A, Vassilopoulou-Sellin R, Gagel RF, Sherman SI, Busaidy NL. The Non-investigational Use of Tyrosine Kinase inhibitors in Thyroid Cancer: Establishing a Standard for Patient Safety and Monitoring. J Clin Endocrinol Metab 98(1):31-42, 2013. e-Pub 2012. PMID: 23185034.
- Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (PHH3) Immuno-reactivity as a Prognostic Marker in Non-Functioning Pituitary Adenomas. Pituitary 15(4):556-61, 2012. e-Pub 2011. PMID: 22120760.
- Ayala-Ramirez M, Chougnet CN, Habra MA, Palmer JL, Leboulleux S, Cabanillas ME, Caramella C, Anderson P, Al Ghuzlan A, Waguespack SG, Deandreis D, Baudin E, Jimenez C. Treatment with Sunitinib for Patients with Progressive Metastatic Pheochromocytomas and Sympathetic Paragangliomas. J Clin Endocrinol Metab 97(11):4040-50, 2012. e-Pub 2012. PMID: 22965939.
- Vu K, Busaidy N, Cabanillas ME, Konopleva M, Faderl S, Thomas DA, O'Brien S, Broglio K, Ensor J, Escalante C, Andreeff M, Kantarjian H, Lavis V, Yeung SC. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk 12(5):355-62, 2012. e-Pub 2012. PMID: 22658895.
- Del Fabbro E, Dev R, Cabanillas ME, Busaidy NL, Rodriguez EC, Bruera E. Extreme hypothyroidism associated with sunitinib treatment for metastatic renal cancer. J Chemother 24(4):221-5, 2012. PMID: 23040687.
- Cabanillas ME, Kantarjian H, Thomas DA, Mattiuzzi GN, Rytting ME, Bruera E, Xiao L, Bekele BN, Foudray MC, Cortes JE. Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: Results of a Randomized Clinical Trial. Cancer 118(3):848-55, 2012. e-Pub 2011. PMID: 21751205.
- Busaidy NL, Cabanillas ME. Differentiated thyroid cancer: management of patients with radioiodine non-responsive disease. J Thyroid Res 2012:618985, 2012. e-Pub 2012. PMID: 22530159.
- Ejaz S, Vassilopoulou-Sellin R, Busaidy NL, Hu MI, Waguespack SG, Jimenez C, Ying AK, Cabanillas M, Abbara M, Habra MA. Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: The University of Texas MD Anderson Cancer Center Experience. Cancer 117(19):4381-9, 2011.
- Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R. Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. J Clin Endocrinol Metab 96(4):997-1005, 2011. e-Pub 2011. PMID: 21289252.
- Mattiuzzi GN, Cortes JE, Blamble DA, Bekele BN, Xiao L, Cabanillas M, Borthakur G, O'Brien S, Kantarjian H.. Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia. Cancer, 2010.
- Cabanillas ME, Waguespack SG, Bronstein Y, Williams MD, Feng L, Hernandez M, Lopez A, Sherman SI, Busaidy NL. Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer the M.D. Anderson Experience (selected for editorial in Nature Reviews and J Clin Endocrinol Metab). J Clin Endocrinol Metab 95(6):2621-4, 2010. e-Pub 2010. PMID: 20392874.
- Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, Lano EA, Matin SF, Nunez RF, Perrier ND, Phan A, Rich TA, Shah B, Williams MD, Waguespack SG. Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94(2):386-91, 2009. e-Pub 2008. PMID: 19017755.
- Torres HA, Aguilera EA, Mattiuzzi GN, Cabanillas ME, Rohatgi N, Sepulveda CA, Kantarjian HM, Jiang Y, Safdar A, Raad II, Chemaly RF. Characteristics and outcomes of respiratory syncytial virus infection in patients with leukemia. Haematologica 92(9):1216-23, 2007. e-Pub 2007. PMID: 17666367.
- Chemaly RF, Torres HA, Aguilera EA, Mattiuzzi G, Cabanillas M, Kantarjian H, Gonzalez V, Safdar A, Raad II. Neuraminidase inhibitors improve outcome of patients with leukemia and influenza: an observational study. Clin Infect Dis 44(7):964-7, 2007. PMID: 17342649.
- Jabbour E, O'Brien S, Kantarjian H, Garcia-Manero G, Ferrajoli A, Ravandi F, Cabanillas M, Thomas DA. Neurological complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood, 2007. PMID: 17209054.
- Weiser MA, Cabanillas M, Vu K, Tamm EP, Wallace MJ, Escalante CP, Bresalier RS. Diagnostic evaluation of patients with a high suspicion of malignancy: comorbidities and clinical predictors of cancer. Am J Med Sci 330(1):11-8, 2005. PMID: 16020994.
Invited Articles
- Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev 40(6):1573-1604, 2019. PMID: 31322645.
- Cabanillas ME, Takahashi S. Managing the adverse events associated with lenvatinib therapy in radioiodine-refractory differentiated thyroid cancer. Semin Oncol 46(1):57-64, 2019. e-Pub 2018. PMID: 30685073.
- Cabanillas ME, Rao SN. Navigating systemic therapy in advanced thyroid carcinoma: from standard-of-care to personalized therapy and beyond. Journal of the Endocrine Society, 2018.
- Cabanillas ME, Zafereo M, Williams MD, Ferrarotto R, Dadu R, Gross N, Gunn GB, Skinner H, Cote G, Grosu HB, Iyer P, Busaidy NL. Recent advances and emerging therapies in anaplastic thyroid carcinoma. F1000 Faculty Reviews 7(87). e-Pub 2018.
- Cabanillas ME, McFadden DG, Durante C. Thyroid Cancer. Lancet 388(10061):2783-2795, 2016. e-Pub 2016. PMID: 27240885.
- Cabanillas ME, Busaidy NL, Khan SA, Brandon Gunn G, Dadu R, Rao SN, Waguespack SG. Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. International Journal of Endocrine Oncology, 2016. e-Pub 2016.
- Cabanillas ME, Zafereo M, Gunn GB, Ferrarotto R. Anaplastic Thyroid Carcinoma: Treatment in the Age of Molecular Targeted Therapy. J Oncol Pract 12(6):511-8, 2016. PMID: 27288464.
- Cabanillas ME, Habra MA. Lenvatinib: Role in thyroid cancer and other solid tumors. Cancer Treat Rev 42:47-55, 2016. e-Pub 2015. PMID: 26678514.
- Cabanillas ME, Dadu R, Hu MI, Lu C, Gunn GB, Grubbs EG, Lai SY, Williams MD. Thyroid Gland Malignancies. Hematol Oncol Clin North Am 29(6):1123-43, 2015. PMID: 26568552.
- Cabanillas ME, Patel A, Danysh BP, Dadu R, Kopetz S, Falchook G. BRAF Inhibitors: Experience in Thyroid Cancer and General Review of Toxicity. Horm Cancer 6(1):21-36, 2015. e-Pub 2014. PMID: 25467940.
- Weitzman SP, Cabanillas ME. The Treatment Landscape in Thyroid Cancer: a Focus on Cabozantinib. Cancer Manag Res 7:265-78, 2015. e-Pub 2015. PMID: 26316818.
- Cabanillas ME, Hu MI, Jimenez C, Grubbs EG, Cote GJ. Treating medullary thyroid cancer in the age of targeted therapy. Int J Endocr Oncol 1(2):203-216, 2014. PMID: 25908961.
- Ganeshan D, Paulson E, Duran C, Cabanillas ME, Busaidy NL, Charnsangavej C. Current Update on Medullary Thyroid Carcinoma. AJR Am J Roentgenol 201(6):W867-76, 2013. PMID: 24261394.
- Dadu R, Cabanillas ME. Optimizing therapy for radioactive iodine-refractory differentiated thyroid cancer: Current state of the art and future directions. Minerva Endocrinol 37(4):335-56, 2012. PMID: 23235190.
- Cabanillas ME, Hu MI, Durand JB, Busaidy NL. Challenges Associated with Tyrosine Kinase Inhibitor Therapy for Metastatic Thyroid Cancer. J Thyroid Res 2011:985780, 2011. e-Pub 2011. PMID: 22007339.
- Rich TA, Cabanillas ME, Perrier ND, Waguespack SG. CDC73-Related Disorders: Hyperparathyroidism-Jaw Tumor Syndrome (HRPT2). Gene Reviews, 2008.
Manuals, Teaching Aids, Other Teaching Publications
- Cabanillas ME. Anaplastic Thyroid Cancer: A Doctor’s Perspective for Patients and Families Living with the Disease. Thyca.org, 2015.
Grant & Contract Support
| Title: | Phase II, open, randomized comparative trial of two different schedules of palonsetron versus ondansetron for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabine |
| Funding Source: | Eisai |
| Role: | Co-Principal Investigator |
| Title: | Phase II, Multicenter, Open-label, Single Arm Trial to Evaluate the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology |
| Funding Source: | Eisai |
| Role: | Principal Investigator |
| Title: | Exelixis Study XL184-008, A Phase 1 Drug-Drug Interaction Study of the Effects of XL184 on the Pharmacokinetics of a Single Oral Dose of Rosiglitazone in Subjects with Solid Tumors |
| Funding Source: | Exelixis |
| Role: | Principal Investigator |
| Title: | An Open-Label, Multi-Center Phase II Study of the BRAF Inhibitor RO5185426 (vemurafenib) in Patients with Metastatic or Unresectable Papillary Thyroid Cancer (PTC) positive for the BRAF V600 Mutation and Resistant to Radioactive Iodine |
| Funding Source: | Roche |
| Role: | Principal Investigator |
| Title: | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of E7080 in 131I-Refractory Differentiated Thyroid Cancer |
| Funding Source: | Eisai |
| Role: | Co-Principal Investigator |
| Title: | A Phase II Trial Using RAD001 for Patients with Radioiodine Refractory Thyroid Cancer |
| Funding Source: | Novartis |
| Role: | Co-Principal Investigator |
| Title: | A Randomized Phase 2 Study of single agent GSK2118436 (BRAFi) vs. combination regimen GSK2118436 (BRAFi) and GSK1120212 (MEKi) in patients with BRAF mutated thyroid carcinoma |
| Funding Source: | The Ohio State University / NCCN |
| Role: | Co-Principal Investigator |
| Title: | Phase II Study of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on First-Line VEGFR-Targeted Therapy |
| Funding Source: | NCI/CTEP |
| Role: | Principal Investigator |
Patient Reviews
CV information above last modified August 14, 2024
Photo Gallery
